Use of Uteroglobin for the Engineering of Polyvalent, Polyspecific Fusion Proteins
Open Access
- 1 September 2009
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (39) , 26646-26654
- https://doi.org/10.1074/jbc.m109.025924
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPublished by Elsevier ,2007
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005
- ED-B fibronectin as a target for antibody-based cancer treatmentsEmerging Therapeutic Targets, 2005
- Recombinant approaches to IgG-like bispecific antibodiesActa Pharmacologica Sinica, 2005
- Tumour vascular targetingNature Reviews Cancer, 2005
- Expression of the Extra Domain B of Fibronectin, a Marker of Angiogenesis, in Head and Neck TumorsThe Laryngoscope, 2003
- A strategy for the isolation of catalytic activities from repertoires of enzymes displayed on phage 1 1Edited by J. KarnJournal of Molecular Biology, 1999
- The fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesisInternational Journal of Cancer, 1994
- Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissuesInternational Journal of Cancer, 1994
- Refinement of the C2221 crystal form of oxidized uteroglobin at 1.34 Å resolutionJournal of Molecular Biology, 1987